Sanford C. Bernstein
https://www.bernsteinresearch.comSanford C. Bernstein, a division of AllianceBernstein, is a research firm.
-
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
-
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
-
KalVista Pharmaceuticals (KALV) Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
-
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
-
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
-
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
-
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
-
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
-
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
-
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
-
KalVista Pharmaceuticals (KALV) Presents New Data on sebetralstat
-
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
-
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
-
KalVista Pharmaceuticals (KALV) Presents New Data
-
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
-
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
-
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
-
KalVista Pharmaceuticals (KALV) Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
-
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE

